» Articles » PMID: 37049852

Marine Fish-Derived Lysophosphatidylcholine: Properties, Extraction, Quantification, and Brain Health Application

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 Apr 13
PMID 37049852
Authors
Affiliations
Soon will be listed here.
Abstract

Long-chain omega-3 fatty acids esterified in lysophosphatidylcholine (LPC-omega-3) are the most bioavailable omega-3 fatty acid form and are considered important for brain health. Lysophosphatidylcholine is a hydrolyzed phospholipid that is generated from the action of either phospholipase PLA or PLA. There are two types of LPC; 1-LPC (where the omega-3 fatty acid at the -2 position is acylated) and 2-LPC (where the omega-3 fatty acid at the -1 position is acylated). The 2-LPC type is more highly bioavailable to the brain than the 1-LPC type. Given the biological and health aspects of LPC types, it is important to understand the structure, properties, extraction, quantification, functional role, and effect of the processing of LPC. This review examines various aspects involved in the extraction, characterization, and quantification of LPC. Further, the effects of processing methods on LPC and the potential biological roles of LPC in health and wellbeing are discussed. DHA-rich-LysoPLs, including LPC, can be enzymatically produced using lipases and phospholipases from wide microbial strains, and the highest yields were obtained by Lipozyme RM-IM, Lipozyme TL-IM, and Novozym 435. Terrestrial-based phospholipids generally contain lower levels of long-chain omega-3 PUFAs, and therefore, they are considered less effective in providing the same health benefits as marine-based LPC. Processing (e.g., thermal, fermentation, and freezing) reduces the PL in fish. LPC containing omega-3 PUFA, mainly DHA (C22:6 omega-3) and eicosapentaenoic acid EPA (C20:5 omega-3) play important role in brain development and neuronal cell growth. Additionally, they have been implicated in supporting treatment programs for depression and Alzheimer's. These activities appear to be facilitated by the acute function of a major facilitator superfamily domain-containing protein 2 (Mfsd2a), expressed in BBB endothelium, as a chief transporter for LPC-DHA uptake to the brain. LPC-based delivery systems also provide the opportunity to improve the properties of some bioactive compounds during storage and absorption. Overall, LPCs have great potential for improving brain health, but their safety and potentially negative effects should also be taken into consideration.

Citing Articles

Comparison of Omega-3 polyunsaturated fatty acids bioavailability in fish oil and krill oil: Network Meta-analyses.

Pham T, Hoang T, Cao P, Le T, Ho V, Vu T Food Chem X. 2025; 24:101880.

PMID: 39974718 PMC: 11838114. DOI: 10.1016/j.fochx.2024.101880.


Compound-Specific Isotope Analysis as a Potential Approach for Investigation of Cerebral Accumulation of Docosahexaenoic Acid: Previous Milestones and Recent Trends.

Ali A, Hachem M, Ahmmed M Mol Neurobiol. 2024; .

PMID: 39633088 DOI: 10.1007/s12035-024-04643-1.


Investigation of Lysophospholipids-DHA transport across an human model of blood brain barrier.

Hachem M, Ali A, Yildiz I, Landry C, Gosselet F Heliyon. 2024; 10(19):e38871.

PMID: 39421371 PMC: 11483317. DOI: 10.1016/j.heliyon.2024.e38871.


Promising Strategies to Reduce the SARS-CoV-2 Amyloid Deposition in the Brain and Prevent COVID-19-Exacerbated Dementia and Alzheimer's Disease.

Navolokin N, Adushkina V, Zlatogorskaya D, Telnova V, Evsiukova A, Vodovozova E Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931455 PMC: 11206883. DOI: 10.3390/ph17060788.


Pork Liver Decomposition Product May Improve Frontal Lobe Function in Humans-Open Trial.

Suzuki M, Sato I, Sato M, Iwasaki H, Saito T, Kimura M Brain Sci. 2024; 14(6).

PMID: 38928586 PMC: 11201879. DOI: 10.3390/brainsci14060586.


References
1.
Lukiw W, Cui J, Marcheselli V, Bodker M, Botkjaer A, Gotlinger K . A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 2005; 115(10):2774-83. PMC: 1199531. DOI: 10.1172/JCI25420. View

2.
Huang Y, Wu R, Claesson H, Frostegard J . Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin Exp Immunol. 1999; 116(2):326-31. PMC: 1905274. DOI: 10.1046/j.1365-2249.1999.00871.x. View

3.
Hasegawa H, Lei J, Matsumoto T, Onishi S, Suemori K, Yasukawa M . Lysophosphatidylcholine enhances the suppressive function of human naturally occurring regulatory T cells through TGF-β production. Biochem Biophys Res Commun. 2011; 415(3):526-31. DOI: 10.1016/j.bbrc.2011.10.119. View

4.
Li L, Zhan Q, Yi K, Chen N, Li X, Yang S . Engineering Lipusu with lysophosphatidylcholine for improved tumor cellular uptake and anticancer efficacy. J Mater Chem B. 2022; 10(11):1833-1842. DOI: 10.1039/d1tb02823e. View

5.
Han X, Gross R . Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev. 2004; 24(3):367-412. DOI: 10.1002/mas.20023. View